Faculty   |   Adjunct Faculty   |   Associated Faculty   |   Research   |   Research Initiatives


Michael Karin
Distinguished Professor of Pharmacology and Pathology
Ph.D., University of California, Los Angeles

Phone: 858-534-1361
Fax: 858-534-8158
E-mail: karinoffice@ucsd.edu

Key Words: Gene Expression, Signal Transduction, Transcription Factors, Oncogenes, Protein Kinases

Dr. Karin was born in Tel Aviv, Israel and received the Bachelor of Science degree in 1975 from Tel Aviv University, with a major in Biology. In 1975 he arrived in the US and in 1979 received a Ph.D. degree in Molecular Biology from the University of California, Los Angeles. Dr. Karin followed his graduate studies with postdoctoral fellowships at the Fox Chase Institute for Cancer Research, working in the laboratory of Dr. Beatrice Mintz, and the laboratory of Dr. John Baxter at the University of California, San Francisco. Dr. Karin joined the faculty at the University of California, San Diego in 1986, where currently he is a Distinguished Professor of Pharmacology.

Dr. Karin has received numerous awards including the Oppenheimer Award for Excellence in Research from the Endocrine Society in 1990, an American Cancer Society Research Professorship in 1999, the C.E.R.I.E.S. Research Award for Physiology or Biology of the Skin in 2000, the Harvey Prize in Human Health in 2011, the Brupbacher Prize in Cancer Research in 2013 and the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology in 2013. Dr. Karin was elected to the National Academy of Sciences in 2005, as a Foreign Associate of EMBO in 2007, and to the Institute of Medicine in 2011. Dr. Karin also serves on several advisory boards and was cofounder of Signal Pharmaceuticals (currently Celgene).

Dr. Karin has spent his entire academic career investigating stress and inflammation signaling covering the entire gamut of research approaches from basic biochemistry through molecular cell biology to animal pathophysiology. After discovering how environmental stress caused by either infection, inflammation or exposure to toxic substances leads to activation of AP-1, NF-κB and other transcription factors, his lab began to examine the role of the key signaling pathways controlling these transcription factors in the pathogenesis of cancer, degenerative and metabolic diseases. The Karin group has identified some of the fundamental mechanisms through which inflammation and obesity promote tumor development and progression and contribute to type II diabetes. They had established the mechanisms through which members of the IL-6 cytokine family contribute to the development of colorectal and liver cancer through activation of STAT3 and other transcription factors. They had also established the complex and cell type specific mechanisms through which NF-κB activation via IκB kinases (IKK) controls development and progression of colon, liver and prostate cancers. They were amongst the first to demonstrate that not only innate immune cells, such as macrophages, but also adaptive immune cells, including T regulatory cells and B lymphocytes, also contribute to tumorigenesis and its progression. Through this work, Dr. Karin has contributed to the founding of the Inflammation and Cancer field.

Selected Publications

Lee, J.H., Budanov, A.V., Park, E.J., Birse, R., Kim, T.E., Perkins, G.A., Ocorr, K., Ellisman, M.H., Bodmer, R., Bier, E., Karin, M. (2010) Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science 327:1223-1228. PMCID: PMC2866632

Holzer, R.G., Pa rk, E.-J., Li, N., Tran, H., Chen, M., Choi, C., Solinas, G., Karin, M. (2011) Saturated fatty acids induce c-Src clustering within membrane subdomains leading to JNK activation. Cell 147:173-184. PMCID: PM C3295636

He, G., Yu, G.-Y., Temkin, V., Ogata, H., Kuntzen, C., Sakurai, T., Sieghart, W., Peck-Radosavljevic, M., Leffert, H.L., Karin, M. (2010) Hepatocyte IKKβ/NF-κB inhibits tumor promotion and progression by preventing oxidative stress driven STAT3 activation. Cancer Cell 17:286-297.

Grivennikov, S., Wang, K., Mucida, D., Stewart, C-A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G., Österreicher, C.H., Hung, K.E., Datz, C., Feng, Y., Fearon, E.R., Oukka, M., Tessarollo, L., Coppola, V., Yarovinsky, F., Cheroutre, H., Eckmann, L., Trinchieri, G., Karin, M. (2012) Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 7423:254-8.

He, G., Dhar, D., Nakagawa, H., Font-Burgada, J., Ogata, H., Jiang, Y., Shalapour, S., Seki, E., Yost, S., Jepsen, K., Frazer, K., Harismendy, O., Hatziapostolou, M., Iliopoulos, D., Suetsugu, A., Hoffman, R., Tateishi, R., Koike, K., Karin, M. (2013) Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155(2):384-96.

Nakagawa, H., Umemura, A., Taniguchi, K., Font-Burgada, J., Dhar, D., Ogata, H., Zhong, Z., Valasek, M., Seki, E., Hidalgo, J., Koike, K., Kaufman, R., Karin, M. (2014) ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 26(3):331-43.

Umemura, A., Park, E.J., Taniguchi, K., Lee, J.H., Shalapour, S., Valasek, M.A., Aghajan, M., Nakagawa, H., Seki, E., Hall, M.N., Karin, M. (2014) Liver Damage, Inflammation and Enhanced Tumorigenesis after Persistent mTORC1 Inhibition. Cell Metabolism 20(1):133-44.

Main address: Department of Pharmacology, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0636
Terms and Conditions of Use
Copyright ©2007 Regents of the University of California. All rights reserved
Site designed by Academic Web Pages